Corruption Probe Could Be A Double-Edged Sword For Chinese Domestic Makers
This article was originally published in PharmAsia News
Executive Summary
Chinese domestic pharmaceutical executives have been mostly tight-lipped about the government’s ongoing anti-corruption investigation, which has mainly targeted multinationals. But recent developments indicate that local companies may soon feel the heat.